P. Dumont et al., RESULT OF SURGERY FOR ESOPHAGEAL CANCER - ANALYSIS OF A SERIES OF 349CASES ACCORDING TO THE TYPE OF RESECTION, Annales de chirurgie, 47(8), 1993, pp. 773-783
Despite obvious improvements in operative and postoperative management
after esophageal resection, surgical treatment of esophageal cancer i
s still disappointing in terms of long term results. The purpose of th
e present study was to verify these poor results satistically and to d
iscuss the value of a modified therapeutic approach. Our experience co
vers 349 esopphageal resections performed between 1979 and 1992. These
patients were predominantly males (93 %) with squamous cell carcinoma
(86 %). The majority of the patients underwent either an Ivor-Lewis (
52 %) or an Akiyama procedure (36 %). Survival was estimated according
to the Kaplan-Meier model. Influence of parameters such as sex, histo
logy, type of resection and TNM-staging was assessed with the << logra
nk >> test. The perioperative mortality was 10%. The non-fatal morbidi
ty rate was 34%, and was most often related to anastomotic leaks. Path
ological staging disclosed a majority of T3 tumors (71 %). The overall
survival rate was 54 % at one year, 28 % at 2 years and 9 % at 5 year
s. This survival was not influenced by either histology (squamous cell
or adenocarcinoma), the type of resection (Ivor-Lewis or Akiyama proc
edure). A slightly superior survival rate was observed after Ivor-Lewi
s procedure and is explained by a lower postoperative complication rat
e. In particular, diffuse N2 disease (abdominal and mediastinal) had a
worse prognosis than localized N2. N1 disease was probably understage
d, since survival was comparable to localized N2. The natural history
was characterized by development of metastases (43 %) rather than by l
ocal recurrence. We conclude that these results may justifiy surgery f
or palliation of dysphagia in so far as the post-operative morbidity i
s reduced, as we observed with Ivor-Lewis procedures. However, improve
ment of long-term survival requires a multimodality oncologic approach
.